Christopher Lau , Brannen Liang , Ourfa Hovsepyan , Tom Shreves , Kenneth Wei
{"title":"综述:隐源性组织性肺炎治疗的研究现状","authors":"Christopher Lau , Brannen Liang , Ourfa Hovsepyan , Tom Shreves , Kenneth Wei","doi":"10.1016/j.pupt.2022.102175","DOIUrl":null,"url":null,"abstract":"<div><p>Cryptogenic organizing pneumonia<span><span><span> is a diffuse interstitial lung disease<span> that starts in the alveolar wall and subsequently expands to the alveolar ducts and respiratory bronchioles. </span></span>Randomized controlled trials<span> are lacking to guide the treatment of cryptogenic </span></span>organizing pneumonia<span>, so treatment decisions and practice guidelines are often based upon observations from case series or expert clinical opinions. The backbone<span> of treatment involves immunosuppression<span> via corticosteroids. In refractory cases, cytotoxic therapy is considered. The evidence that supports the use of these regimens are limited. The goal of this scoping review is to conduct a systematic search of the literature to determine what regimens have been utilized to treat steroid refractory organizing pneumonia and to characterize the evidence supporting their use.</span></span></span></span></p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"77 ","pages":"Article 102175"},"PeriodicalIF":3.3000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics\",\"authors\":\"Christopher Lau , Brannen Liang , Ourfa Hovsepyan , Tom Shreves , Kenneth Wei\",\"doi\":\"10.1016/j.pupt.2022.102175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Cryptogenic organizing pneumonia<span><span><span> is a diffuse interstitial lung disease<span> that starts in the alveolar wall and subsequently expands to the alveolar ducts and respiratory bronchioles. </span></span>Randomized controlled trials<span> are lacking to guide the treatment of cryptogenic </span></span>organizing pneumonia<span>, so treatment decisions and practice guidelines are often based upon observations from case series or expert clinical opinions. The backbone<span> of treatment involves immunosuppression<span> via corticosteroids. In refractory cases, cytotoxic therapy is considered. The evidence that supports the use of these regimens are limited. The goal of this scoping review is to conduct a systematic search of the literature to determine what regimens have been utilized to treat steroid refractory organizing pneumonia and to characterize the evidence supporting their use.</span></span></span></span></p></div>\",\"PeriodicalId\":20799,\"journal\":{\"name\":\"Pulmonary pharmacology & therapeutics\",\"volume\":\"77 \",\"pages\":\"Article 102175\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary pharmacology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094553922000669\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553922000669","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics
Cryptogenic organizing pneumonia is a diffuse interstitial lung disease that starts in the alveolar wall and subsequently expands to the alveolar ducts and respiratory bronchioles. Randomized controlled trials are lacking to guide the treatment of cryptogenic organizing pneumonia, so treatment decisions and practice guidelines are often based upon observations from case series or expert clinical opinions. The backbone of treatment involves immunosuppression via corticosteroids. In refractory cases, cytotoxic therapy is considered. The evidence that supports the use of these regimens are limited. The goal of this scoping review is to conduct a systematic search of the literature to determine what regimens have been utilized to treat steroid refractory organizing pneumonia and to characterize the evidence supporting their use.
期刊介绍:
Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews.
Research Areas Include:
• All major diseases of the lung
• Physiology
• Pathology
• Drug delivery
• Metabolism
• Pulmonary Toxicology.